See what’s new.
Gene therapy developed at Duke to be commercialized by a local biotechnology company
A universal gene editing therapy for Pompe disease, invented in the lab of Duke Professor Dwight Koeberl, is licensed for further development by local start-up GeneVentiv.
10 Years, 60 Startups, $105 Million – and Counting: Duke Capital Partners Leads the Way in Alumni Investing
From its start as one of the first alumni-led venture groups of its kind, Duke Capital Partners continues to connect Duke alumni investors with innovative Duke-affiliated startups – and train the next generation of venture…
Breath of Life: Duke Inventors Secure $5M for Novel Oxygenation Startup
Duke clinician partners with Duke engineers to tackle an elusive critical care challenge: Can oxygen be delivered directly into the bloodstream through a catheter?
VQ Biomedical secures $5M, including a seed round led by Harbright, WIN, and DCP
VQ Biomedical is a Duke University start-up and DCP portfolio company resulting from the collaboration Duke clinicians and engineers.
Colleagues off the Court: Duke and UNC Champion Research and Innovation on Capitol Hill
From Google’s search to 3D printing, from MRIs to mRNA vaccines, countless products and services that make our lives better started as university born innovations from research.
Durham agtech startup Avalo secures $11M in funding
Avalo is a Duke agtech start-up based on technology developed by former postdoc Mariano Alvarez (Biology, Trinity) and Professor Cynthia Rudin (CS, Trinity).
Donald Patrick McDonnell, PhD, Wins 2025 Baxter Prize for Entrepreneurship
Professor Donald McDonnell (PCB, SOM) is a serial inventor with multiple commercialized technologies, including FDA-approved breast cancer drug ORSERDU.
Tune Therapeutics Names John McHutchison as CEO and Chairman of the Board
New Tune CEO John McHutchison has held professorships and associate directorships at SOM and DCRI. Tune is a Duke spinout and DCP portfolio company.
Duke Translational Chaperones help researchers secure over $6.5M in translational funding
In their pilot year, the new team at OTC worked with Duke life sciences PIs to position their research for maximal translational impact. Who will they help next?